| Popis: |
With the rapid development of nanotechnology in the recent decade, novel DNA and RNA delivery systems for gene therapy have become available that can be used instead of viral vectors. These non-viral vectors can be made of a variety of materials, including inorganic nanoparticles, carbon nanotubes, liposomes, protein and peptide-based nanoparticles, as well as nanoscale polymeric materials. They have as advantages over viral vectors a decreased immune response, and additionally offer flexibility in design, allowing them to be functionalized and targeted to specific sites in a biological system with low cytotoxicity.gene therapy keeps hopes a life for the treatment of a wide range of diseases such as cancer, nano particles are now known as promising carriers for the effective and safe vectors of genes to specific cells or tissues. This could provide alternative therapies for conventional approaches that use viruses as gene carriers. The expression of genetic material such as DNA, RNA into cells and tissues has raised considerable hopes for therapeutic and diagnostic purposes. But getting nucleic acids into the cell also faces challenges. These challenges are less for non-virus carriers as a gene and drug vectors method than for viral or free vectors and are therefore considered less risky and more appropriate. of expanding nonverbal nano carriers, we will look at a few of these nano carriers, penicillin, PEI, PLGA, silica, block copolymer, Quantum dot, gold nano particles, and common carbon nano tubes. Problems include the use of nano particles such as polymer nano particles, liposomes, solid lipid particles, in targeted gene vectors will be investigated. Gene-based therapy is the intentional modulation of gene expression in specific cells to treat pathological conditions. This modulation is accomplished by introducing exogenous nucleic acids such as DNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides. Given the large size and the negative charge of these macromolecules, their delivery is typically mediated by carriers or vectors. In this Review, we introduce the biological barriers to gene delivery in vivo and discuss recent advances in material sciences, nanotechnology and nucleic acid chemistry that have yielded promising non-viral delivery systems, some of which are currently undergoing testing in clinical trials. The diversity of these systems highlights the recent progress of gene-based therapy using non-viral approaches. |
